Anbio Biotechnology Class A Ordinary Shares (NNNN) Revenue History
Annual and quarterly revenue from 2021 to present
NNNN Revenue Over Time (2021–2024)
NNNN Revenue Growth History
2 of 3 years with positive growth- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- +431.7%
- FY2023 revenue growth
- -71.5%
- FY2024 revenue growth
- +21.9%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $2.5M | -36.0% |
| Q2 2024 | $6.3M | +91.2% |
| Q4 2023 | $4.0M | — |
| Q2 2023 | $3.3M | — |
NNNN Revenue Analysis (2021–2024)
Current Revenue & Growth
As of June 21, 2026, Anbio Biotechnology Class A Ordinary Shares (NNNN) generated trailing twelve-month (TTM) revenue of $16.1 million, reflecting significant decline in growth of -36.0% year-over-year. The most recent quarter (Q4 2024) recorded $2.5 million in revenue, down 60.0% sequentially.
Historical Growth Trajectory
NNNN's historical revenue data shows a 3-year CAGR of +22.7%. Anbio Biotechnology Class A Ordinary Shares's highest annual revenue of $23.5 million was recorded in 2022.
Peer Comparison
Compared to Healthcare sector peers — including CLOV (+48.4% YoY), ACHC (+6.8% YoY), and QDEL (-3.9% YoY) — NNNN has underperformed the peer group in revenue growth. Compare NNNN vs CLOV →
NNNN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NNNNCurrent | $16M | -36.0% | - | 24.4% | |
 CLOV | $1.9B | +48.4% | +23.4% | -4.4% | |
 ACHC | $3.3B | +6.8% | +9.7% | 11.7% | |
 QDEL | $2.7B | -3.9% | +10.4% | -33.7% | |
 IDXX | $4.3B | +13.1% | +9.7% | 31.6% |
NNNN Historical Revenue Data (2021–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $8.2M | +21.9% | $5.9M | 71.9% | $2.0M | 24.4% |
| 2023 | $6.7M | -71.5% | $3.4M | 50.1% | $2.0M | 29.2% |
| 2022 | $23.5M | +431.7% | $12.6M | 53.4% | $10.2M | 43.3% |
| 2021 | $4.4M | - | $2.5M | 57.4% | $2.5M | 55.5% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NNNN — Frequently Asked Questions
Quick answers to the most common questions about buying NNNN stock.
Is NNNN's revenue growth accelerating or slowing?
NNNN revenue is declining -36.0% year-over-year. TTM revenue fell to $16M, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is NNNN's revenue history from 2021 to 2026?
Anbio Biotechnology Class A Ordinary Shares (NNNN) revenue history spans 2021 to 2026. TTM revenue as of 2026 is $16M, growing at -36.0% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is NNNN's long-term revenue growth rate (CAGR)?
Anbio Biotechnology Class A Ordinary Shares's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -36.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for NNNN.
Why does NNNN's quarterly revenue fluctuate?
NNNN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Anbio Biotechnology Class A Ordinary Shares's revenue data from 2021 to 2026 shows full historical quarterly detail on this page.
How is NNNN's revenue distributed by segment?
NNNN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does NNNN's revenue compare to industry peers?
Anbio Biotechnology Class A Ordinary Shares (NNNN) with TTM revenue of $16M and -36.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.